Health & Fitness
Thu, September 6, 2012
PRINCETON, N.J.--([ BUSINESS WIRE ])--[ Advaxis, Inc ]., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that Thomas Moore, Chairman and CEO of Advaxis, will present at the Rodman & Renshaw 14th Annual Healthcare Conference on September 10th from 4:30-4:55pm EST in the Palm Room of the Waldorf=Astoria Hotel in New York.
Slides from the presentation will be available on the [ Advaxis website ] following the presentation.
About Advaxis, Inc.
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete antigen/adjuvant fusion protein(s) designed to redirect the powerful immune response all human beings have to the bacteriumto the cancer itself.
In April 2012, Advaxisa lead construct, ADXS-HPV, was selected as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines. The ViE awards, sponsored by Novartis Vaccines and Diagnostics, were created to recognize the accomplishments and contributions of companies and individuals in the vaccine industry over the previous 12 months. Additional information is available at the [ World Vaccine Congress website ].
ADXS-HPV is being evaluated in 4 Phase 2 clinical trials that are open for enrollment for HPV-associated diseases: CIN 2/3 (US study, Clinical Trials.gov Identifier NCT01116245), locally advanced cervical cancer (GOG/NCI US study, Clinical Trials.gov Identifier NCT01266460), recurrent/refractory cervical cancer (India), and head & neckcancer (University of Liverpool/CRUK UK study, Clinical Trials.gov Identifier NCT0CT01598792). Over fifteen (15) distinct constructs are in various stages of development, developed directly by the Company and through strategic collaborations with recognized centers of excellence such as: the [ National Cancer Institute ], [ Cancer Research a" UK ], the [ Wistar Institute ], the [ University of Pennsylvania ], the [ University of British Columbia ], the [ Karolinska Institutet ], and others. For more information please visit: [ advaxis.com ] | [ Facebook ] | [ twitter ] | [ LinkedIn ]
Forward-Looking Statements
This news release contains forward-looking statements,including, butnot limited to: statements as to the anticipated timing of clinical studies and other business developments, statements as to the development of new constructs, expectations as to the adequacy of our cash balances to support our operations for specified periods of time and as to the nature and level of cash expenditures, expectations as to market opportunities, our ability to take advantage of those opportunities, and the risk factors set forth from time to time in Advaxis' SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2011, which is available at [ www.sec.gov ]. The Company undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.You are cautioned not to place undue reliance on any forward-looking statements.
